AUCTUS PUBLICATIONS ________________________________________ New Zealand Energy (NZ CN)C: Financial update – New Zealand has received short term loans totalling C$0.48 mm from Charlestown Energy Partners and a company controlled by New Zealand’s Chairman. The loans, which were issued with an original issuance discount of 10%. are unsecured and non-convertible, with interest payable at 15% per annum and repayment is due on August 27, 2025, The company now intends to complete a private placement. ...
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: IBERDROLA, OHLA, REDEIA, REPSOL. El mercado de divisas, nuevo foco de atención Jornada mixta en las bolsas europeas, que cotizaron divididas con la vista puesta en el dólar y el nuevo retroceso que sufrió ayer, cayendo a mínimos de 2022. En el STOXX 600 R. Básicos e Industriales fueron los sectores que más subieron, frente a las mayores caídas de Hogar y B. de Consumo (sectores con bastante exposición a dólar). Por el lado macro, en EE.UU. el PIB 1...
NEWS SUMMARY: IBERDROLA, OHLA, REDEIA, REPSOL. Spotlight now on the currency market It was a mixed session on European stock markets, which were a mixed bag with all eyes on the dollar and the drop it suffered yesterday, falling to a low since 2022. In the STOXX 600, Basic Materials and Industrials were the sectors rising the most, with Household Goods and Consumer Goods falling the most (sectors highly exposed to the USD). On the macro side, in the US the 1Q’25 GDP was lowered in its third rea...
Neinor secures €225mn with record €1.2bn demand to fund the AEDAS Tender Offer acquisition It has successfully executed an accelerated bookbuild (ABB) with over €1.2bn of demand and c.6x oversubscribed Neinor Homes sets a new benchmark in the equity capital markets pricing the ABB at a +10% premium to pre-tender offer announcement levels - raising capital at €15.25/share The capital raise was 100% allocated to top tier institutional investors, increasing Neinor’s free float to ~€600 million, a key milestone in enhancing trading depth, index relevance, and long-term investor alignment ...
NEWS SUMMARY: ACCIONA/ACCIONA ENERGÍA, AMPER, IBERDROLA, NEINOR HOMES. Stock markets looking to return to 2025 highs The ceasefire between Iran and Israel continued to fuel stock markets at both sides of the Atlantic, with the Ibex returning to 14,000 points. Thus, in the STOXX 600, all sectors except Energy (due to the drop in oil prices) saw gains, led by Travel&Leisure and Construction. On the macro side, in Germany the IFO index climbed slightly more than expected for the sixth consecutive ...
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: ACCIONA, ACCIONA ENERGÍA, AMPER, IBERDROLA, NEINOR HOMES. Las bolsas con ganas de volver a los máximos del año El alto el fuego entre Irán e Israel siguió impulsando las bolsas a ambos lados del Atlántico, con el Ibex recuperando los 14.000 puntos. En el STOXX 600 todos los sectores menos Energía (por la caída del precio del petróleo) subieron, liderados por Viajes&Ocio y Construcción. Por el lado macro, en Alemania el IFO repuntó ligeramente más d...
Press Release: Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation Ongoing phase 2 study evaluating riliprubart for the potential prevention and treatment of active antibody-mediated rejection in kidney transplant recipientsRiliprubart was also designated orphan drug for the investigational use in chronic inflammatory demyelinating polyneuropathy in the US and EU Paris, June 25, 2025. The US Food and Drug Administ...
Communiqué de presse : Le riliprubart est désigné comme médicament orphelin aux États-Unis pour le rejet induit par les anticorps dans la transplantation d’organes solides Le riliprubart est désigné comme médicament orphelin aux États-Unis pour le rejet induit par les anticorps dans la transplantation d’organes solides Étude de phase 2 en cours évaluant le riliprubart pour la prévention et le traitement potentiels du rejet actif induit par les anticorps chez les receveurs de transplantation du reinLe riliprubart a également été désigné comme médicament orphelin pour l’utilisation expérimen...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.